Whale Optimization for Energy Efficient Healthcare System in WBAN Environment

A Patent Review on SARS Coronavirus Papain‐Like Protease (PLpro) Inhibitors

“…[79] Approximately 2 weeks later, Cadila Healthcare Limited researchers filed a patent on 29 September 2021 (WO 2022/070048; Table 1), describing naphthalene ethylbenzamide GRL-0617 analogs with a range of SARS-CoV-2 PL pro inhibitory activities (Figure 33). [55] The most potent inhibitor, compound 197, exhibited an IC 50 of 0.5 μM. In a cell-based assay using SARS-CoV-2-infected Vero E6 cells, it demonstrated an EC 50 of 1.0 μM.…”

“…In a cell-based assay using SARS-CoV-2-infected Vero E6 cells, it demonstrated an EC 50 of 1.0 μM. [55] In comparison, the EC 50 of CoV M pro inhibitor nirmatrelvir on SARS-CoV-2-infected Vero E6 cells was reported to be 75 � 8 nM, indicating compound 197 lacks sufficient potency for further drug development. [79] SciFinder ® structure searches on the exemplified inhibitors, including compound 197 did not reveal any follow-up publications on their SARS-CoV-2 PL pro inhibitory activities.…”